natgillin/translations-raw huggingface dataset:
• metastatic breast cancer, when the first treatment has stopped working and standard treatment including an ‘anthracycline' (another type of cancer medicine) is not suitable.
• metastatskog raka dojke kad prva terapija više nije djelotvorna, a standardna terapija koja uključuje "antraciklin" (drugi lijek protiv raka) nije dostupna.
For metastatic adenocarcinoma of the pancreas, Abraxane was studied in one main study involving 861 patients who received either Abraxane in combination with gemcitabine or gemcitabine alone.
Kod metastatskog adenokarcinoma gušterače, Abraxane je ispitivan u jednom glavnom ispitivanju koje je uključivalo 861 bolesnika, koji su primili ili Abraxane u kombinaciji s gemcitabinom ili samo gemcitabin.
In metastatic breast cancer Abraxane is given on its own every three weeks.
Kod metastatskog raka dojke, Abraxane se primjenjuje sam svaka tri tjedna.
In addition, Abraxane given in combination with gemcitabine was shown to improve survival in patients with metastatic adenocarcinoma of the pancreas compared with treatment with gemcitabine alone and was effective in combination with carboplatin in the treatment non-small cell lung cancer.
Nadalje, Abraxane primijenjen u kombinaciji s gemcitabinom pokazao je djelotvornost u boljem preživljenju bolesnika s metastatskim adenokarcinomom gušterače u usporedbi s terapijom samo gemcitabinom, te je bio djelotvoran u kombinaciji s karboplatinom u liječenju raka nemalih stanica pluća.
Overall, in the main study, 31% of the women receiving Abraxane responded to treatment (72 out of 229), compared with 16% of the women receiving conventional paclitaxel-containing medicines (37 out of 225).
(72 od 229), u usporedbi sa 16% žena koje su primile konvencionalne lijekove koji sadrže paklitaksel (37 od 225).
This makes it easy to prepare a suspension of paclitaxel, which can be infused into a vein.
To omogućava laganu pripremu otopine paklitaksela, koju se infuzijom unosi u venu.
For additional information, see the summary of product characteristics (also part of the EPAR).
Dodatne informacije pročitajte u sažetku opisa svojstava lijeka (također dio EPAR-a).
In metastatic adenocarcinoma of the pancreas, Abraxane was shown to improve overall survival.
Kod metastatskog adenokarcinoma gušterače, Abraxane je pozitivno djelovao na opće poboljšanje preživljenja.
The recommended dose of Abraxane is 100 mg per square metre of body surface area.
Preporučena doza lijeka Abraxane je 1000 mg po kvadratnom metru tjelesne površine.
In metastatic adenocarcinoma of the pancreas Abraxane is given in 4-week treatment cycles.
Kod metastatskog adenokarcinoma gušterače Abraxane se primjenjuje u terapijskim ciklusima od četiri tjedna.
In contrast, Abraxane was more effective than conventional paclitaxel-containing medicines in patients who had taken other treatments for metastatic breast cancer before.
Međutim, Abraxane se pokazao djelotvornijim od konvencionalnih lijekova koji sadrže paklitaksel u bolesnika koji su prethodno primili terapiju za metastatski rak dojke.
What is Abraxane used for?
Za što se Abraxane koristi?
Abraxane given on its own was compared with a conventional paclitaxel-containing medicine given together with other medicines to reduce side effects.
Abraxane koji je bio primijenjen sam uspoređen je s konvencionalnim lijekom koji sadrži paklitaksel, primjenjivan zajedno s drugim lijekovima za ublažavanje nuspojava.
What benefit has Abraxane shown during the studies?
Koje su koristi lijeka Abraxane utvrđene u ispitivanjima?
How is Abraxane used?
Kako se Abraxane koristi?
Abraxane paclitaxel
Abraxane paklitaksel
How does Abraxane work?
Kako djeluje Abraxane?
For the full list of restrictions with Abraxane, see the package leaflet.
Potpuni popis ograničenja za lijek Abraxane potražite u uputi o lijeku.
How has Abraxane been studied?
Kako je Abraxane ispitivan?
For the full list of all side effects reported with Abraxane, see the package leaflet.
Potpuni popis nuspojava zabilježenih pri primjeni lijeka Abraxane potražite u uputi o lijeku.
Treatment may be repeated for up to five consecutive days.
Liječenje se može ponavljati do pet uzastopnih dana.
10 DATE OF REVISION OF THE TEXT <{MM/YYYY}>
DATUM REVIZIJE TEKSTA <{MM/GGGG}>
No data have been presented on overdoses in adult cats.
Nema podataka o predoziranju kod odraslih mačaka.
ATCvet code: QA04AD90
ATCvet kod: QA04AD90
Maropitant is effective against vomiting.
Maropitant je učinkovit protiv povraćanja.
For administration by subcutaneous injection, see also “special precautions for use in animals” (section 4.5).
Za primjenu supkutanom injekcijom, vidjeti također „Posebne mjere opreza prilikom primjene na životinjama” (dio 4.5).
C. STATEMENT OF THE MRLs Not applicable.
IZVJEŠĆE O MRL-u Nije primjenjivo.
Wash hands after use.
Nakon primjene potrebno je oprati ruke.
If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.
Ako zamijetite bilo koju nuspojavu, čak i one koje nisu navedene u ovoj uputi VMP-a ili smatrate da veterinarsko-medicinski proizvod ne djeluje, molimo obavijestite svog veterinara.
Excipients: Benzyl alcohol (E1519)
Pomoćne tvari: benzilni alkohol (E1519)
PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic group: Antiemetics.
FARMAKOLOŠKA SVOJSTVA Farmakoterapijska grupa: Antiemetici.
Although maropitant has been demonstrated to be effective in both the treatment and prevention of emesis induced by chemotherapy, it was found more efficacious if used preventively.
Iako se maropitant pokazao učinkovitim za liječenje i sprječavanje povraćanja prouzročenog kemoterapijom, ustanovljeno je da je djelotvorniji ako se daje preventivno.
11.1 mg For the full list of excipients, see section 6.1.
11,1 mg Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
This centre consists of several brainstem nuclei (area postrema, nucleus tractus solitarius, dorsal motor nucleus of the vagus) that receive and integrate sensory stimuli from central and peripheral sources and chemical stimuli from the circulation and the cerebro-spinal fluid.
Centar se sastoji od nekoliko jezgri moždanog stabla (area postrema, nucleus tractus solitarius, dorzalna motorička jezgra vagusa) koje primaju i integriraju osjetne podražaje iz centralnih i perifernih izvora te kemijske podražaje iz cirkulacije i cerebrospinalne tekućine.
Vomiting is a complex process coordinated centrally by the emetic centre.
Povraćanje je složen proces, centralno koordiniran iz centra za povraćanje.
Signs of nausea in dogs including excessive salivation and lethargy might remain after treatment.
Znakovi mučnine u pasa, uključujući pojačano slinjenje i letargiju, mogu se nastaviti i poslije liječenja.
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products in the same syringe.
U nedostatku ispitivanja kompatibilnosti ovaj veterinarsko-medicinski proizvod se ne smije miješati s drugim veterinarsko-medicinskim proizvodima u istoj štrcaljki.
Do not use this veterinary medicinal product after the expiry date which is stated on the label of the vial after EXP.
Ne koristite veterinarsko-medicinski proizvod poslije isteka roka valjanosti naznačenog na etiketi bočice poslije EXP.
• For the treatment of vomiting, in combination with other supportive measures.
• Za liječenje povraćanja u kombinaciji s drugim pomoćnim mjerama.
During clinical studies maropitant plasma levels conferred efficacy from 1 hour after administration.
Tijekom kliničkih ispitivanja razine maropitanta u plazmi postigle su djelotvornost 1 sat nakon primjene.
For subcutaneous or intravenous use in dogs and cats.
Za supkutanu ili intravensku primjenu u pasa i mačaka.
In very rare cases, anaphylactic type reactions (allergic oedema, urticaria, erythema, collapse, dyspnoea, pale mucous membranes) may occur.
U vrlo rijetkim slučajevima mogu se javiti reakcije anafilaktičkog tipa (alergijski edem, urtikarija, eritem, kolaps, dispneja, blijede mukozne sluznice).
Maropitant undergoes cytochrome P450 (CYP) metabolism in the liver.
Maropitant podliježe metabolizmu citokroma P450 (CYP) u jetri.
Amber glass type I vial closed with a coated bromobutyl rubber stopper and aluminium cap in a cardboard box.
Bočica od smeđeg stakla tip I, zatvorena prevučenim čepom od brombutilne gume i aluminijskom kapicom u kartonskoj kutiji.
Use only according to the benefit-risk assessment by the responsible veterinarian, because conclusive reproductive toxicity studies have not been conducted in any animal species.
Primijeniti samo nakon što nadležni veterinar provede procjenu koristi i rizika, s obzirom da ispitivanja reproduktivne toksičnosti nisu provedena kod nijedne životinjske vrste.
Pack sizes of 1 vial of 10 ml, 20 ml, 25 ml or 50 ml.
Veličine pakiranja od 1 bočice, od: 10 ml, 20 ml, 25 ml ili 50 ml.
Good veterinary practice indicates that antiemetics should be used in conjunction with other veterinary and supportive measures such as dietary control and fluid replacement therapy while addressing the underlying causes of the vomiting.
Dobra veterinarska praksa pokazuje da antiemetike treba koristiti zajedno s drugim veterinarskim i pomoćnim mjerama, kao što su dijetna prehrana i nadoknada izgubljene tekućine dok se djeluje na osnovni uzrok povraćanja.
Prevomax must not be mixed with other veterinary medicinal products in the same syringe as its compatibility with other products has not been tested.
Prevomax se ne smije miješati s drugim veterinarsko-medicinskim proizvodima u istoj štrcaljki jer kompatibilnost s drugim proizvodima nije ispitana.
THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE
13. RIJEČI „SAMO ZA PRIMJENU NA ŽIVOTINJAMA” I UVJETI ILI OGRANIČENJA U POGLEDU OPSKRBE I PRIMJENE
Comment: Given the small vial size(s), would it not be preferable to replace these by “SC, IV"
Napomena: S obzirom na veličine bočica, bolje je zamijeniti oznakama “s.c., i.v."
Therefore, it is recommended to administer the veterinary medicinal product prior to administration of the chemotherapeutic agent.
Stoga se preporučuje davanje veterinarsko-medicinskog proizvoda prije davanja kemoterapeutika.
Maropitant is a neurokinin 1 (NK1) receptor antagonist, which acts by inhibiting the binding of substance P, a neuropeptide of the tachykinin family.
Maropitant je antagonist receptora neurokinina 1 (NK1) koji djeluje inhibicijom vezivanja tvari P, neuropeptida iz obitelji tahikinina.
• For the prevention of perioperative nausea and vomiting and improvement in recovery from general anaesthesia after use of the μ-opiate receptor agonist morphine.
• Za sprječavanje mučnine i povraćanja u perioperativnom razdoblju te poboljšanje u oporavku od opće anestezije nakon primjene, agonista μ-opijatnih receptora morfina.
In case of accidental self-injection seek medical advice immediately and show the package leaflet or the label to the physician.
U slučaju nehotičnog samoinjiciranja, odmah potražite savjet liječnika i pokažite mu uputu o VMP-u ili etiketu.
The anti-emetic efficacy of maropitant against central and peripheral emetics was demonstrated in experimental studies including apomorphine, cisplatin and syrup of ipecac (dogs) and xylazine (cats).
Antiemetička djelotvornost maropitanta protiv centralnih i perifernih emetika dokazana je u eksperimentalnim ispitivanjima koja su uključivala apomorfin, cisplatin i sirup ipekakuane (psi) te ksilazin (mačke).
Substance P is found in significant concentrations in the nuclei comprising the emetic centre and is considered the key neurotransmitter involved in vomiting.
Tvar P se u značajnim koncentracijama nalazi u jezgrama koje obuhvaćaju centar za povraćanje i smatra se ključnim neurotransmiterom uključenim u čin povraćanja.
Manufacturer responsible for batch release: Produlab Pharma B.V.
Proizvođač odgovoran za puštanje serije u promet: Produlab Pharma B.V.
Betadex sulfobutyl ether sodium Benzyl alcohol (E1519) Citric acid, anhydrous Sodium hydroxide Water for injections
Popis pomoćnih tvari natrijev sulfobutileter betadeks benzilni alkohol (E1519) limunska kiselina, bezvodna natrijev hidroksid voda za injekcije
The duration of effect is approximately 24 h and therefore treatment can be given the night before administration of an agent that may cause emesis e.g. chemotherapy.
Trajanje učinka iznosi približno 24 sata pa se stoga može primijeniti noć prije primjene tvari koja može prouzročiti povraćanje, npr. kemoterapija.
11.1 mg A clear, colourless to light yellow solution.
11,1 mg Bistra, bezbojna do svijetložuta otopina.
4.8 Interaction with other medicinal products and other forms of interaction
Interakcije s drugim medicinskim proizvodima i drugi oblici interakcija
4.7 Use during pregnancy, lactation or lay
Primjena tijekom graviditeta, laktacije ili nesenja
EXP Once broached use within 56 days.
EXP Jednom otvorenu treba upotrijebiti unutar 56 dana.
Injecting the product at refrigerated temperature may reduce pain at injection.
Injektiranje rashlađenog proizvoda može smanjiti bol prilikom aplikacije.
Vomiting can be associated with serious, severely debilitating conditions including gastrointestinal obstructions; therefore, appropriate diagnostic evaluations should be employed.
Povraćanje može biti povezano s ozbiljnim, teškim iscrpljujućim stanjima, uključujući gastrointestinalne zastoje (smetnje) i stoga je potrebno provesti ciljane dijagnostičke pretrage.
In the case of accidental eye exposure, flush the eyes with plenty of water and seek medical attention.
U slučaju slučajnog kontakta s očima, isprati s puno vode i potražiti liječničku pomoć.
Vomiting can be associated with serious, severely debilitating conditions and the cause should be investigated.
Povraćanje može biti povezano s ozbiljnim, teškim iscrpljujućim stanjima te je zbog toga potrebno istražiti uzrok.
THE WORDS “FOR ANIMAL TREATMENT ONLY” For animal treatment only.
RIJEČI „SAMO ZA PRIMJENU NA ŽIVOTINJAMA” Samo za primjenu na životinjama.
CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Veterinary medicinal product subject to prescription.
UVJETI ILI OGRANIČENJA U POGLEDU OPSKRBE I PRIMJENE Veterinarsko-medicinski proizvod izdaje se na veterinarski recept.
People with known hypersensitivity to maropitant should administer the veterinary medicinal product with caution.
Osobe preosjetljive na maropitant trebaju oprezno primjenjivati veterinarsko medicinski proizvod.
As maropitant is accumulated in the body during a 14 day treatment period due to metabolic saturation, careful monitoring of liver function and any adverse events should be implemented during long term treatment.
Budući da se tijekom liječenja od 14 dana maropitant akumulira u tijelu zbog zasićenja metabolizma, kod dugotrajnog liječenja treba pažljivo pratiti funkciju jetre i pojavu bilo kojeg štetnog događaja.
As the pharmacokinetic variation is large and maropitant accumulates in the body after once daily repeated administration, lower doses than recommended might be sufficient in some individuals and when repeating the dose.
S obzirom da je farmakokinetička varijacija velika i da se maropitant nakuplja u organizmu nakon ponovljene primjene jedanput dnevno, kod nekih jedinki doze niže od preporučenih mogu biti dovoljne, kada se primjena doze ponavlja.
Prevomax should be used with caution in animals suffering from or with predisposition for heart diseases.
Prevomax treba upotrebljavati s oprezom u životinja koje boluju od srčane bolesti ili imaju predispozicije za tu bolest.
In laboratory studies, maropitant has been shown to be a potential eye irritant.
U laboratorijskim ispitivanjima pokazalo se da maropitant može nadražiti oči.
• For the treatment and prevention of nausea induced by chemotherapy.
• Za liječenje i sprječavanje mučnine prouzročene kemoterapijom.
By inhibiting the binding of substance P within the emetic centre, maropitant is effective against neural and humoral (central and peripheral) causes of vomiting.
P u centru za povraćanje, maropitant učinkovito djeluje protiv neuralnih i humoralnih (centralnih i perifernih) uzroka povraćanja.
The elimination t1/2 following intravenous dosing was approximately 5.8 h.
Poluvrijeme eliminacije t1/2 nakon intravenske primjene doze iznosilo je približno 5,8 sati.
For the major metabolite 10.4% of the maropitant dose was recovered in urine and 9.3% in faeces.
Pretragom na glavni metabolit u urinu, nađeno je 10,4 % doze maropitanta i 9,3 % doze u fecesu.
To prevent vomiting, the veterinary medicinal product solution for injection should be administered more than 1 hour in advance.
Za sprječavanje povraćanja, veterinarsko-medicinski proizvod, otopinu za injekciju treba davati više od 1 sat unaprijed.
Maropitant is metabolised in the liver and therefore should be used with caution in dogs and cats with liver disease.
Maropitant se metabolizira u jetri pa je stoga potreban oprez kad se daje psima i mačkama s bolešću jetre.
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE Name and address of the manufacturer responsible for batch release Produlab Pharma B.V.
PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE U PROMET Naziv i adresa proizvođača odgovornog za puštanje serije u promet Produlab Pharma B.V.
The bioavailability of maropitant after subcutaneous administration in dogs was 90.7%.
Bioraspoloživost maropitanta nakon supkutane primjene u pasa bila je 90,7 %.
QUANTITY OF THE ACTIVE SUBSTANCE(S) 10 mg/ml
KOLIČINA DJELATNE(IH) TVARI 10 mg/ml
A variety of in vitro assays have demonstrated that maropitant binds selectively at the NK1 receptor with dose-dependent functional antagonism of substance P activity.
Raznim vrstama in vitro ispitivanja dokazano je selektivno vezanje maropitanta za receptor NK1 s funkcionalnim antagonizmom prema aktivnosti tvari P, ovisnim o dozi.
CYP2D15 and CYP3A12 were identified as the canine isoforms involved in the hepatic biotransformation of maropitant.
CYP2D15 i CYP3A12 identificirani su kao pseći izooblici uključeni u biotransformaciju maropitanta u jetri.
TARGET SPECIES Dogs, cats
CILJNE VRSTE ŽIVOTINJA Psi, mačke
In cats, moderate to severe response to injection is very commonly observed (in approximately one third of cats).
Kod mačaka se vrlo često (otprilike kod jedne trećine mačaka) javlja umjerena do teška reakcija na injekciju.
Plasma protein binding of maropitant in dogs is more than 99%.
Vezanje maropitanta na proteine plazme iznosi kod pasa više od 99 %.
The responsible veterinarian should make a benefit-risk assessment before using the veterinary medicinal product in dogs less than 8 weeks of age, or in cats less than 16 weeks of age, or in pregnant or lactating bitches and cats.
Nadležni veterinar mora procijeniti koristi i rizike prije primjene veterinarsko medicinskog proizvoda u pasa mlađih od 8 tjedana ili u mačaka mlađih od 16 tjedana ili u nosećih ili dojnih kuja i mačaka.
Due to the frequent occurrence of transient pain during subcutaneous injection, appropriate animal restraining measures may have to be applied.
Zbog učestalog pojavljivanja prolazne boli prilikom supkutane injekcije, životinju će možda trebati sputati na odgovarajući način.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals, including isolated reports treated).
Učestalost nuspojava određena je u skladu sa sljedećim pravilima: - vrlo česte (više od 1 na 10 tretiranih životinja pokazuju nuspojavu(e) - česte (više od 1 ali manje od 10 životinja na 100 tretiranih životinja) - manje česte (više od 1 ali manje od 10 životinja na 1.000 tretiranih životinja) - rijetke (više od 1 ali manje od 10 životinja na 10.000 tretiranih životinja) - vrlo rijetke (manje od 1 životinje na 10.000 tretiranih životinja, uključujući izolirane slučajeve).
Maropitant has been shown to be a potential eye irritant, and in the case of accidental eye exposure, flush the eyes with plenty of water and seek medical attention.
Maropitant može nadražiti oči pa je u slučaju nehotičnog kontakta s očima potrebno isprati oči s puno vode i potražiti liječničku pomoć.
Use only according to the benefit-risk assessment by the responsible veterinarian.
Primijeniti samo nakon procjene odnosa koristi i rizika nadležnog veterinara.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Glass vial
OSNOVNI PODACI KOJI SE MORAJU NALAZITI NA MALIM UNUTARNJIM PAKIRANJIMA
Shelf life after first opening the immediate packaging: 56 days.
Rok valjanosti poslije prvog otvaranja unutarnjeg pakiranja: 56 dana.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Outer carton
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU Kutija
The veterinary medicinal product should be used with caution in animals suffering from or with predisposition for cardiac diseases as maropitant has affinity to Ca- and K-ion channels.
Veterinarsko-medicinski proizvod treba koristiti s oprezom kod jedinki koje imaju srčane bolesti ili onih koje imaju predispoziciju za te bolesti, jer maropitant ima afinitet prema kanalima iona kalcija i kalija.
MARKETING AUTHORISATION NUMBER(S) EU/2/17/211/001-004 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 19/06/2017
BROJ(EVI) ODOBRENJA ZA STAVLJANJE U PROMET EU/2/17/211/001-004
The veterinary medicinal product should not be used concomitantly with Ca-channel antagonists as maropitant has affinity to Ca-channels.
Veterinarsko-medicinski proizvod ne smije se davati istodobno s antagonistima kalcijevih kanala zbog afiniteta maropitanta prema kalcijevim kanalima.
Maropitant is highly bound to plasma proteins and may compete with other highly bound medicines.
Maropitant se opsežno veže na proteine plazme te se može natjecati s drugim lijekovima koji imaju istu osobinu.
Products such as Prevomax should be used in conjunction with other supportive measures such as dietary control and fluid replacement therapy, as recommended by your veterinary surgeon.
Proizvod kao Prevomax treba koristiti u kombinaciji s drugim potpornim mjerama, poput dijetne prehrane i nadoknade izgubljene tekućine, prema preporuci veterinara.
The volume of distribution at steady-state (Vss) was 2.3 l/kg and systemic clearance was 0.51 l/h/kg.
Volumen distribucije u stabilnom stanju (Vss) bio je 2,3 l/kg, a sustavni klirens 0,51 l/h/kg.
The use of the veterinary medicinal product against vomiting due to motion sickness is not recommended.
Ne preporučuje se upotreba veterinarsko-medicinskog proizvoda za sprječavanje povraćanja uzrokovanog bolešću kretanja.
• For the prevention of vomiting except that induced by motion sickness.
• Za sprječavanje povraćanja osim onoga izazvanog bolešću kretanja.
Specific pharmacovigilance requirements: The PSURs for Prevomax shall be submitted at the same frequency as for Cerenia (reference product).
PSUR-evi za Prevomax podnosit će se jednako često kao i za VMP Cerenia (referentni proizvod).
Plasma protein binding of maropitant in cats was estimated to be 99.1%.
Procijenjeno je da vezanje maropitanta za proteine plazme iznosi u mačaka 99,1 %.
c/ Balmes 202, 6a 08006 Barcelona
Dechra Veterinary Products S.L.U. c/ Balmes 202, 6a 08006 Barcelona
Renal clearance is a minor route of elimination, with less than 1% of a 1 mg/kg subcutaneous dose appearing in the urine as either maropitant or its major metabolite.
Izlučivanje putem bubrega manje je značajan put eliminacije, pa se pri supkutanoj dozi od 1 mg/kg u urinu pojavi manje od 1 % maropitanta ili njegova glavnog metabolita.
Following repeated subcutaneous administration of once-daily doses of 1 mg/kg bodyweight for five consecutive days, accumulation was 146%.
Nakon ponovljene supkutane primjene doza od 1 mg/kg tjelesne težine jednom dnevno tijekom pet uzastopnih dana, akumulacija je iznosila 146 %.
CYP1A and CYP3A-related enzymes were identified as the feline isoforms involved in the hepatic biotransformation of maropitant.
Enzimi povezani s CYP1A i CYP3A identificirani su kao mačji izooblici uključeni u biotransformaciju maropitanta u jetri.